Hitchwood Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Hitchwood Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-81,993	Closed	-$23.7M	–	57
2018 Q2	$23.7M	Sell	81,993 -68,007	-45%	-$18.8M	0.74%	31
2018 Q1	$37.5M	Sell	150,000 -270,000	-64%	-$68.7M	1.82%	21
2017 Q4	$100M	Buy	420,000 +70,000	+20%	+$17M	3.76%	8
2017 Q3	$77.8M	Sell	350,000 -50,000	-13%	-$11.3M	3.32%	9
2017 Q2	$90.5M	Buy	400,000 +100,000	+33%	+$21.8M	3.72%	9
2017 Q1	$59.8M	Buy	+300,000	New	+$57.8M	2.22%	23

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Hitchwood Capital Management's BIO Position: Q3 2018 in Review

Hitchwood Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2018, closing a stake of 81,993 shares — an estimated $23.7M sold.

Hitchwood Capital Management first reported a position in BIO in Q1 2017 and held it in 6 quarters. The position peaked at $100M in Q4 2017. 343 funds tracked by Wall St. Rank hold BIO as of Q3 2018.

Hitchwood Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2018 after selling out during the quarter.
Hitchwood Capital Management sold 81,993 Bio-Rad Laboratories Class A shares in Q3 2018, an estimated $23.7M.
Hitchwood Capital Management first reported a position in Bio-Rad Laboratories Class A in Q1 2017 and held it in 6 quarters.
Hitchwood Capital Management's Bio-Rad Laboratories Class A position peaked at $100M in Q4 2017.
343 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2018.

Based on Hitchwood Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.